Facebook
Twitter
LinkedIn
Forward
Today in IBD: Managing IBD in the Era of Covid-19
Managing Inflammatory Bowel Disease (IBD) in the Era of COVID-19 will thoroughly review the multi-society global recommendations for assessment and management of IBD during the coronavirus pandemic. This includes data on the evolving epidemiology of COVID-19, and specifically what is known about it in patients with IBD. It will provide state-of-the-art education regarding best-practices for telehealth and other non-endoscopic and distance management strategies, evidence supporting non-invasive monitoring of both disease activity and anti-inflammatory therapies, and strategies for de-intensification, cessation, and restarting IBD therapies safely and effectively during this unique and challenging time. Key topics of this timely webinar include: Overview of SARS-CoV-2; COVID-19 and IBD; The optimum management of IBD during the SARS-CoV-2 pandemic; Best practices for telehealth now and into the future; Monitoring patients with IBD during extraordinary times.
Target Audience
Gastroenterology physicians, fellows, nurse practitioners, and physician assistants involved in the management of patients with inflammatory bowel disease
Learning Objectives
After successful completion of this CME/CE activity, participating members of the IBD care team should be better able to:
- Identify the specific concerns and considerations of patients with IBD during the COVID-19 pandemic
- Develop standard testing and treatment protocols for IBD patients with known or suspected infection with SARS-CoV-2
- Incorporate non-invasive disease monitoring strategies into the management of IBD to assess remission and risks of clinical relapse
- Develop appropriate methods to de-intensify, stop, and restart medical therapies in IBD patients with known or suspected infection with SARS-CoV-2
Additional Information
Marla Dubinsky, MD
Advisory Board/Consultant: AbbVie, Amgen, Arena, Boehringer Ingelheim, Celgene, Lilly, Genentech, Gilead Sciences, Janssen, Pfizer, Merck, Prometheus, Projections Research, Rebiotix, Takeda; Shareholder: Trellus Health; Grant/Research Support: AbbVie, Pfizer, Prometheus; Intellectual Property/Patents: MI Test Health
David Rubin, MD
Consultant: AbbVie, Abgenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene/Syneos, Check-cap, Dizal, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences, GlaxoSmithKline, Janssen, Lilly, Manana Therapeutics, Narrow River Management, Pfizer, Prometheus, Reistone, Seres, Shire, Takeda, Target PharmaSolutions, Techlab; Stock Options: Abgenomics, Biomica; Grant/Research Support: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
Planners' and Reviewers' Disclosures
Reviewers
Anne Sullivan, MSN, APRN, CNP, Advisory Board: Pfizer
Elizabeth Spencer, MD has no relevant relationships.
Planning Team
John JD Juchniewicz, MCIS, CHCP; Natalie Kirkwood, RN, BSN, JD; Debi Palestina; Jason Schlatter have no relevant relationships.
Conflict of Interest Disclosure Policy
According to the disclosure policy of the American Academy of CME, Inc., all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
Disclosure of Unlabeled Use
This activity may review off-label or investigational information.
This activity is jointly provided by the American Academy of CME, Inc. and Cornerstones Health.
Joint Accreditation
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Cornerstones Health. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA PRA Category 1 Credits TM
Designation Statement
American Academy of CME, Inc., designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hours
Designation Statement
American Academy of CME, Inc., designates this educational activity for 1.5 contact hours (.9 pharmacotherapeutic contact hours).
California: Provider approved by the California Board of Registered Nursing, Provider Number CEP16993 for 1.5 contact hours.
AAPA Category 1 CME Credits
Designation Statement
American Academy of CME, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until July 23, 2021. PAs should only claim credit commensurate with the extent of their participation.
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
This course is offered through myCME. To take this course you will be redirected to myCME's website. You must have an account with myCME in order to complete this activity.
MOCINGBIRD continues to work with our CME partner network to provide courses directly to you. We appreciate your patience as we work toward that goal!